Is Thymosin Alpha-1 FDA Approved? The Immune Peptide Approved in 35 Countries

The Short Answer

Thymosin Alpha-1 is not FDA-approved in the United States. But it holds a regulatory status that no other peptide on this site can claim: it is an approved pharmaceutical product in over 35 countries, backed by thousands of published studies and large-scale clinical trials. The brand name is Zadaxin (generic name: thymalfasin).

It also has FDA Orphan Drug designation for hepatocellular carcinoma, meaning the FDA has formally recognized its potential for treating a rare condition and has granted incentives for its development in the US. The designation is not an approval, but it means the FDA has reviewed preliminary evidence and deemed it warranting further investigation.

Approved in 35+ Countries

Zadaxin has been approved for medical use in over 35 countries, with the largest markets in Asia and Europe. The primary approved indications are:

Chronic hepatitis B. Thymosin Alpha-1 enhances the immune response against the hepatitis B virus, increasing rates of viral clearance when used alongside standard antivirals. This is its most extensively studied indication, with multiple large randomized controlled trials.

Chronic hepatitis C. Used as an adjunct to interferon-based therapy to improve sustained virological response rates. (Less relevant since the introduction of direct-acting antivirals like sofosbuvir, which have largely replaced interferon-based regimens.)

Immune enhancement. Approved in several countries for immune modulation in immunocompromised patients, including those undergoing chemotherapy or those with primary immunodeficiency.

Vaccine adjuvant. Used to enhance immune response to vaccines in elderly or immunocompromised populations whose vaccine response is typically suboptimal.

FDA Orphan Drug Designation

The FDA's Orphan Drug designation is granted to drugs intended for diseases affecting fewer than 200,000 people in the US. Receiving the designation means the FDA has reviewed the sponsor's preliminary evidence and agreed the compound warrants development for that indication. Benefits include tax credits for clinical trial costs, waived FDA fees, and 7 years of marketing exclusivity upon approval.

Thymosin Alpha-1 received Orphan Drug designation for hepatocellular carcinoma (HCC), a primary liver cancer. This is not the same as FDA approval, but it does mean the FDA has formally reviewed and acknowledged the compound. It is the closest any immune-modulating peptide has come to the FDA approval pathway.

How Thymosin Alpha-1 Works

Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland, the organ where T-cells mature. Its primary mechanism is immune system modulation:

Critically, Thymosin Alpha-1 is an immune modulator, not a simple immune stimulant. It enhances immune function when it is underactive (immunodeficiency, chronic infection, aging) while helping balance the immune response to prevent overactivation. This bidirectional modulation is why it has been studied for both immune deficiency and inflammatory conditions.

Why Is It Not FDA Approved in the US?

The answer is market strategy, not science. SciClone Pharmaceuticals focused its regulatory efforts on markets where the hepatitis B burden was highest and the commercial opportunity was largest: China, Southeast Asia, and parts of Europe. The hepatitis B prevalence in the US is much lower, making the US market less commercially attractive for this specific indication.

Running a US Phase 3 trial for FDA approval would have cost hundreds of millions of dollars. The company made a strategic decision to allocate those resources to markets where the patient population was larger and the regulatory pathway was already established. This is a commercial decision, not a reflection of safety or efficacy concerns.

The 4,400+ published studies, the approvals in 35+ countries, and the FDA Orphan Drug designation collectively represent a level of clinical validation that exceeds virtually any other compounded peptide. The absence of US FDA approval is a regulatory gap, not an evidence gap.

US Availability Today

In the United States, Thymosin Alpha-1 is available as a compounded medication under federal pharmacy compounding law. A licensed provider must prescribe it. A licensed pharmacy must prepare it. PeRx ships Thymosin Alpha-1 fully reconstituted and ready to use.

Frequently Asked Questions